Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carelizumab + Nab-paclitaxel +/- Apatinib in Advanced TNBC
NCT04335006Phase 3Terminated
- Sponsor
- Hengrui
- Start
- Jul 2020
- Primary completion
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of camrelizumab in triple-negative breast cancer (TNBC) (3 arms), sponsored by Hengrui. Primary endpoint: Progression-Free Survival up to 42 months. Started Jul 2020; status: terminated.
02
Drugs
camrelizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04335006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04335006.